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Abstract
Background: Diabetes shared medical appointments (SMAs) and reciprocal peer support programs have been
found in efficacy trials to help adults with diabetes improve their self-management and achieve short-term gains in
clinical and patient-centered outcomes. In order to translate this evidence to system-level interventions, there is a
need for large-scale, pragmatic trials that examine the effectiveness, implementation, and costs of SMAs and
reciprocal peer support across diverse settings.
Methods: The Shared Health Appointments and Reciprocal Enhanced Support (SHARES) study is a multisite, cluster
randomized trial that is evaluating the effectiveness and implementation of SMAs with and without an additional
reciprocal Peer-to-Peer (P2P) support program, when compared to usual care. The P2P program comprises periodic
peer support group sessions and telephone contact between SMA participant pairs to promote more effective
diabetes self-management. We will examine outcomes across three different treatment groups: (1) SMAs, (2) SMAs
plus P2P, and (3) usual care. We will collect and analyze data over a 2.5-year implementation period at five
geographically diverse Veterans Affairs (VA) health systems. The primary outcome is the relative change in
hemoglobin A1c over time. Secondary outcomes are changes in systolic blood pressure, antihypertensive
medication use, statin use, and insulin initiation over the study period. The unit of analysis is the individual, adjusted
by the individual’s SMA group (the cluster). We will use mixed methods to rigorously evaluate processes and costs
of implementing these programs in each of the clinic settings.
Discussion: We hypothesize that patients will experience improved outcomes immediately following participation
in SMAs and that augmenting SMAs with reciprocal peer support will help to maintain these gains over time. The
results of this study will be among the first to examine the effects of diabetes SMAs alone and in conjunction with
P2P in a range of real-life clinical settings. In addition, the study will provide important information on contextual
factors associated with successful program implementation.
Trial registration: ClinicalTrials.gov, ID: NCT02132676. Registered on 21 August 2013.
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The Centers for Disease Control and Prevention cur-
rently estimate that at least one out of three Americans
will develop type-2 diabetes in their lifetime [1]. While
there are now effective treatments for diabetes, success
of these therapies depends on how well patients self-
manage over a sustained period of time. Yet, many
patients face multiple barriers to effective diabetes self-
management (SM) [2, 3]. To meet this challenge,
Veterans Affairs (VA) health facilities are working to
develop and evaluate low-cost, scalable approaches to
increase between face-to-face visit SM support [4].
Shared medical appointments (SMAs) for diabetes
bring patients with the same chronic condition together
with an interdisciplinary team of providers to provide
SM education and support. Several recent meta-analyses
of randomized controlled trials (RCTs) of diabetes SMAs
have found that SMAs are more effective than usual care
in improving hemoglobin A1c levels and systolic blood
pressure (SBP) [5–7]. However, most studies of SMAs to
date have examined outcomes during, and immediately
after, participation in SMAs. There is growing evidence
that many patients do not succeed in maintaining SM
and clinical improvements achieved through short-term
programs [8–11]. Maintaining achieved gains may be es-
pecially difficult for patients who lack sustained social
support. Both receiving and providing social support is
associated with improved SM and clinical outcomes
[12–15]. With increasing resource and staff constraints,
novel approaches are needed to help patients sustain SM
improvements that do not rely exclusively on face-to-
face or professionally led programs.
The Peer-to-Peer (P2P) support program, which in-
volves reciprocal peer support in the form of telephone
calls between paired participants and periodic patient-
directed group sessions, may be a particularly effective
complement to SMAs. In an efficacy trial, Heisler et al.
found the P2P program to be more effective than nurse
care management in improving glycemic control and
other diabetes outcomes [16]. The P2P program takes
SMAs a step further by providing a long-term infra-
structure for the peer support component to continue
on a regular basis beyond face-to-face meetings, some-
thing especially important for patients who face barriers
to accessing care. By augmenting SMAs with the P2P
program, SMA participants can continue to work to-
gether to improve SM behaviors and sustain gains
achieved through the SMAs.
Figure 1 summarizes the mechanisms through which
peer support may enhance chronic disease behaviors
and health outcomes.
Objectives
In order to advance understanding of the value and chal-
lenges of implementing SMAs and the P2P program in
real-world settings, we designed a multisite pragmatic
trial at five VA health care systems in five diverse
geographic locations. The study will evaluate whether
the addition of the P2P program can improve patients’
SM and outcomes above and beyond the use of SMAs
alone—in a combined program called the Shared Health
Appointments and Reciprocal Enhanced Support
(SHARES) program – over a longer period of time. Our
objectives are to:
1. Evaluate the effect of SMAs and SMAs + P2P on
diabetic patients’ glycemic control, systolic blood
pressure, statin use, and insulin initiation at 6 and 12
months post enrollment compared to usual care.
2. Assess the impact of SMAs and SMAs + P2P on
service utilization and patient-centered outcomes,
including patients’ satisfaction with VA care,
diabetes-specific quality of life and social support at
6 and 12 months post enrollment.
3. Conduct a post-implementation interpretive
formative evaluation using constructs from the
Consolidated Framework for Implementation
Research (CFIR).
4. Estimate program costs using staff effort data
obtained throughout implementation.
Fig. 1 Conceptual framework of hypothesized effects of peer support on diabetes care attitudes, self-management (SM), and clinical outcomes
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Trial design
The study design is a multisite, cluster randomized trial.
Randomization will take place in two stages. First, eli-
gible patients will be randomized to usual care versus
active treatment. Patients who are invited to participate
in SMAs will then be randomized by SMA cohort (the
cluster) into one of two conditions: (1) SMAs, or (2)
SMAs plus P2P (SHARES). This study involves the col-
lection and analysis of both quantitative and qualitative
data during a 23-month implementation period (May
2016 to April 2019). Qualitative data was also collected
at VA sites before the study period to identify potential
barriers to implementation and will be collected after
the study period to evaluate the implementation process,
attainment, and sustainability.
Analyses will include all patients randomized to usual
care and patients randomized to active treatment. To
maintain comparability of the groups, we are including all
patients randomly invited to participate in SMAs in the
analysis. Thus, the analysis represents a comparison of
outcomes of all patients invited for treatment with the
outcomes of those eligible patients who were not invited
to participate. To restrict our analysis in this comparison
to only those patients who agreed to participate in SMAs
would result in selection effects among the intervention
population and a loss of the advantages of randomization.
Using a mixed-methods approach for data collection
and analyses, summative data on clinical outcomes and
service utilization will be obtained from VA databases for
all patients invited to participate in the programs and
those randomly not selected for invitation to SMAs. Out-
comes will be measured at baseline and at 6 and 12
months post enrollment. When possible, clinical data will
be used, especially as data on the clinical measures of
interest is already collected as part of patient care. For the
two active treatment arms (SMA-only, SMA + P2P), la-
boratory tests at baseline and 6 months will be ordered
through SMA staff as part of the SMA program. As we
will have no contact with the usual-care group, we will
need to rely on laboratory values ordered as part of their
routine clinical care. Thus, we may have more missing
values for hemoglobin A1cs, although guidelines recom-
mend checking hemoglobin A1cs at least every 6 months
in patients with glycemic control that is not at goal.
For patients enrolled in the SMA-only and SMA+ P2P
groups who sign a HIPAA authorization, data on patient-
centered outcomes will be obtained from surveys. Qualita-
tive data on organizational factors influencing program
implementation and characteristics of usual care at each
site will be obtained via semistructured interviews of staff
at each site. Data on staff time required to implement
SMAs and P2P will also be collected to calculate the over-
all costs of program implementation.
Methods
Study setting
Implementation of the programs takes place within the
outpatient primary care clinics at five different VA
health care systems: Ann Arbor, MI; Palo Alto, CA;
Providence, RI; Sacramento, CA; and West Haven, CT.
Because this is a study of effectiveness and not efficacy,
it is important to implement the programs within the
existing context of each of the participating sites; for
example, each of the sites already has an established
SMA protocol. The protocols differ across sites in SMA
frequency and duration of program. However, as a result
of our collaboration with the sites during the start-up
period, they established comparable programs in terms
of group size, key elements included in their SMA cur-
riculum, patient eligibility criteria, patient selection
process, and total dose of SMAs (each SMA consists of
6–8 h of meeting time for each cohort). Table 1 refers to
the SMA characteristics at each of the sites.
Eligibility criteria
Patients
Using automated clinical data, patients are identified as
having diabetes if, within the previous 12 months, they
had: (1) one hospitalization or two outpatient visits with a
diabetes-related International Classification of Diseases,
version 10 (ICD-10) code or (2) at least one prescription
for a diabetes medication (excluding glucose-monitoring
supplies). To be eligible for the study, diabetic patients
need to have had a hemoglobin A1c in the prior 6 months
that was greater than 7.5% if aged under 70 years or
greater than 8.0% if aged 70 years or older. Using ICD-10
diagnostic codes and automated data, we exclude patients
if they had a serious psychiatric illness (bipolar disorder,
dementia, schizophrenia, or personality disorders) or ac-
tive substance abuse (except for nicotine dependence). In
addition, patients under the age of 18 years are excluded.
Table 1 Shared medical appointment (SMA) characteristics at participating sites
Ann Arbor Palo Alto Providence Sacramento West Haven
Session length 2 h 2 h 1 h 1 h 1.5 h
Number of sessions 4 4 8 8 4
Frequency Every month Every 2 weeks Every 2 weeks Every week Every 3 months
Total dose 8 h 8 h 8 h 8 h 6 h
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VA clinical leadership and staff
As part of the formative evaluations, approximately five
to eight VA employees at each of the participating sites
have been, or will be, asked to participate in semistruc-
tured interviews before, during, and after implementa-
tion of SHARES. These employees include the director
of primary care, clinicians participating in the SMAs, the
P2P group facilitator, and a random sample of two
primary care providers. The primary purpose of the




Individuals who are randomized to usual care will receive
standard primary and specialty care for their diabetes as de-
termined by their clinicians. Patients are randomly assigned
to usual care throughout the recruitment period for the
purpose of maintaining consistent data collection windows.
Active treatment: SMA-only
Individuals in the SMA-only arm are invited to partici-
pate in a SMA. At each participating site, the SMA be-
gins with introductions and information sharing,
followed by a more open group discussion that also has
an educational component. The group discussion facili-
tates peer interaction and support. In addition to teach-
ing patients about medications and insulin management
(e.g., administration, self-monitoring, supplies, self-
titration), instruction during the SMAs includes other
important areas of diabetes SM such as blood pressure
and lipid control, diet, exercise, and stress management.
Patients also receive instruction in developing short-
term action plans. The patients choose an area of dia-
betes SM that is important to them to work on and then
decide on a concrete step that they feel confident they
can take toward meeting this goal over the next week
(detailing what they would like to do, how often, how
long, where, and ways they will address possible barriers)
[17]. The last component of the visit is the clinical
component (examination and management) where
medication changes and titration are made if necessary.
Active treatment: SMA + P2P (SHARES program)
Individuals in the SMA + P2P arm are invited to partici-
pate in the SMA, as above. In addition, they are invited
to participate in the P2P program between SMA sessions
and/or after the completion of the series of SMA ses-
sions. The P2P program consists of patient-directed
group sessions and telephone calls between matched
SMA participants.
P2P group sessions
Following an SMA session, participants attend the first
P2P group session where they are matched by the P2P
facilitator with another SMA participant. Participants
are also provided with a brief introduction to peer com-
munication skills to help guide them in providing and
receiving peer support. The curriculum used was devel-
oped and successfully used in Heisler’s prior RCT, which
is based on evidence-based Motivational Interviewing
(MI) approaches [18, 19]. Although the emphasis is on
enabling patients to assist their partners, MI concepts
will also help participants with their own behavioral
tasks. The training and participation in peer support is
thus expected to promote each patient’s own SM
while enhancing their skills in providing support to
others; one of the key mechanisms by which peer
support may work is to “activate” patients through
supporting their peer.
Drop-in group peer support sessions led by a peer fa-
cilitator are offered between SMA visits at West Haven
(which holds SMAs every 3 months) and at approxi-
mately 6-week intervals after patients have finished with
the series of SMAs at all other sites. Attendance at the
drop-in group sessions is optional. The group sessions
provide participants the opportunity for peer support by
facilitating discussion of concerns and experiences with
living with diabetes, setting and follow-up of SM goals,
and shared problem-solving strategies.
Telephone calls between peers
Participants are encouraged to talk with their partner
once per week, with the primary purpose of discussing
progress made on SM goals and/or barriers encountered.
A research staff member contacts participants 2 weeks
after they have been paired to determine if there are any
issues with the partners connecting. If a P2P participant
reports problems with their partner, both members of
the peer support pair are given the option of being
assigned to a different partner from other partners
requesting reassignment. If participants do not wish to
be paired to another partner, they have the option of
joining an existing pair who are willing to take on an
additional partner or of continuing to participate only in
the group sessions. Numbers of partner changes and
reasons for changes are tracked.
Figure 2 outlines the flow of patients through the pro-
grams and the research evaluations.
Outcomes
The principal analysis is a comparison of the effects of
participation in the two active treatment arms (SMA-only,
SMA + P2P) compared to usual care with respect to the
primary outcome of change in hemoglobin A1c level and
secondary outcomes of change in SBP, antihypertensive
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medication use, statin use, and insulin initiation. We will
examine the difference between patient average baseline
values of hemoglobin A1c and SBP in 6-month windows
preceding baseline and following the 6- and 12-month
post-enrollment evaluation periods for both active treat-
ment and inactive control groups.
As part of aim 2, we will evaluate change in patient-
centered outcomes as reported on patient surveys at
baseline and 6 and 12 months post enrollment. These
outcomes include service utilization, satisfaction with
VA care, diabetes-specific distress, diabetes social sup-
port, and diabetes SM behaviors.
Participant timeline
Table 2 outlines the data collection points of the
research evaluation.
Sample size
We chose five VA health systems in which to implement
the program based on our estimation of feasibility of im-
plementation, given budget and time constraints. We
estimated that we could conduct 10–16 SMA groups per
site (equally distributed between SMAs and SMAs + P2P)
with 8–14 people per group. At a minimum, this would
equate to 560 people in active treatment, including an
Fig. 2 Study flow diagram
Table 2 Participant timeline
Study period
Pre-enrollment Enrollment 6 months post enrollment 12 months post enrollment
Group allocation X
Patient surveys X X X
Patient interviews X
Clinical data (Veterans Administration (VA) database) X X X
Staff interviews X X
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equal number of inactive controls. In this scenario, we can
detect a 0.5% difference in hemoglobin A1c and a 5-
mmHg decline in SBP between the active treatment
groups and controls.
Recruitment
Patients can participate in SMAs and P2P even if they
elect not to participate in the surveys and interviews. In
addition, their medical record data will still be extracted
for the overall assessment of changes in clinical mea-
sures and utilization in the three arms over the
12-month study period. There will be two methods of
recruitment: existing mechanisms (e.g., clinical referral)
and data pull.
Existing mechanisms
During the start-up period of this project, many of the
participating sites established a strong referral base and
high participation rate in their SMAs. All patients sched-
uled for an SMA, who meet our eligibility criteria, are
mailed a research packet containing the study informa-
tion letter, a HIPAA authorization, and the baseline
survey. Informed consent is implied by the receipt of a
completed baseline survey. If a completed survey has
not been received prior to the patient attending an
SMA, the patient is approached at the SMA to deter-
mine interest in the research study.
Data pull
Each quarter, we will pull a list of eligible patients (iden-
tified from VA datasets), withholding a set number of
random patients reserved for the inactive treatment arm.
Invitation letters describing the SMAs, P2P, and the re-
search study are mailed to these patients. Unless patients
respond that they do not wish to participate, the letters
are followed with a telephone call by research staff to
further describe the programs and to schedule interested
patients in an upcoming SMA. Those scheduled for
SMAs are asked if they are willing to participate in the
research study and a research packet is sent to those
who express interest in the study.
Group allocation
Patients are randomized to the usual-care group at the
time of each quarterly data pull. All eligible patients in
the dataset are assigned a random number and sorted in
ascending order. Based on each site’s recruitment target,
a set number of patients at the top of this list are then
put into the usual-care group. Scheduled SMA groups
are randomized to receive P2P by the coordinating cen-
ter using a random number generator prior to starting
participant recruitment. Patients interested in SMAs are
scheduled into the next available SMA, regardless of
whether or not the participant is interested in P2P. In
the case of recruitment through an existing clinical
mechanism, the scheduler is not aware of which SMA
groups will be offering P2P as an additional optional
component. All participants attending an SMA that is
being offered P2P will be included in the SMA + P2P
analysis group, regardless of whether or not they elect to
participate in the optional P2P program.
Blinding (masking)
Group allocation will be coded in the dataset provided




Data on participating patients is obtained from surveys,
interviews, and VA databases. The three surveys (base-
line, 6 months, and 12 months) and interviews (for a
subset of participants) are obtained for research
purposes only. Patients are contacted by mail, with tele-
phone follow-up when needed, to request follow-up
survey completion. Existing medical record data for the
inactive treatment arm will also be used.
VA employees
Data about VA employees is obtained through interviews
and used for both program implementation and research
purposes.
Active treatment fidelity
To the extent that differences will inevitably exist across
sites, we are collecting data on differences in execution
of the SMA and P2P programs. A member of the re-
search staff attends all SMA sessions for a subset of co-
horts to complete a fidelity checklist. The study team
discusses any issues in SMA fidelity during biweekly all-
team calls. When issues are identified, the research team
works with the SMA facilitators to urge concordance
with SMA VA national guidelines. Dr. Susan Kirsh, who
drafted these guidelines and is a consultant on the pro-
ject, provides additional training to SMA facilitators
when needed. The health behavior coordinators (HBCs)
or designee at each of the sites attends the initial P2P
group session of a cohort (immediately following an
SMA) to complete a fidelity checklist and provide imme-
diate feedback to the facilitators. Additional assessments
are conducted of subsequent P2P group sessions at least
once every few months. The HBC provides additional
training to P2P facilitators as needed to resolve any is-
sues identified during these fidelity checks.
Data management
Throughout the study, Central Institutional Review
Board (CIRB) and HIPAA guidelines are followed to
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ensure the privacy and integrity of the data collected. To
minimize the risk of a breach of confidentiality, we take
the following steps. First, each patient recruited for the
research component of the study (surveys and possible
interview) is assigned a unique study ID. Other than
study ID, no identifying information is maintained with
patients’ study data, either in hardcopy or electronic for-
mats. All electronic data, including audio files, is stored
on a VA server behind the VA firewall. Following tran-
scription of an audio file, all identifying data (e.g., names
of other patients, providers, facilities) in the transcript is
removed and the audio file is deleted.
Furthermore, study staff members sign a pledge of
confidentiality and understand that breach of confidenti-
ality is grounds for dismissal. Study staff members are
required to complete annual training on privacy and
HIPAA, as well as biannual training on human subject
protection. All research findings will be presented in ag-
gregate only.
Survey data is coded and entered by local study team
members. Surveys are then sent to the coordinating cen-
ter, where a second pass data entry is completed and the
surveys are securely stored.
Statistical methods
Aim 1
The analysis of hemoglobin A1c values will take the
form of a “difference in differences” analysis whereby we
will compare final hemoglobin A1c measurements con-
trolling for the baseline hemoglobin A1c measurement
among all persons who agreed to participate in one of
the two active treatment arms and the inactive control
arm. We will use a two-level mixed-effects model with
outcome hemoglobin A1c as the dependent variable and
including treatment indicator (SMA-only, SMA + P2P,
usual care) as the independent variable, baseline
hemoglobin A1c and site as covariates, and the group ID
as the level-two grouping variable. The coefficient of the
treatment variable will indicate the degree by which the
change in hemoglobin A1c for the SMA-only and SMA
+ P2P arms is different from the change in hemoglobin
A1c seen in the control arm. An identical analysis will
be used for the SBP secondary outcome. Insulin initi-
ation and antihypertensive and statin use will be ana-
lyzed using a multilevel ordinal logistic regression with
the same basic approach. In a second analysis, we will
assess whether there are differences in these outcomes
between participants in the SMA-only versus SMA +
P2P arms to examine whether there is additional im-
provements among SMA participants also offered P2P.
All analyses are intention-to-treat analyses. For the
first analysis, as we are using an inactive control, in
order to get a comparable group we have to define the
active intervention population as those people randomly
selected to receive an invitation for active treatment.
This broadening of the active treatment population will
dilute the effect of the intervention as the treatment arm
will include the estimated 50% of subjects who decline
to participate. In fact, the acceptance rate is itself an in-
teresting parameter to estimate. Furthermore, we will
conduct a Complier Average Causal Effect analysis
(CACE) in order to estimate the effect of the small
group treatment format among the compliers (those
who agree to participate). In the second analysis com-
paring outcomes between the SMA-only and SMA +
P2P groups, the comparable groups can be defined as
people who agree to participate in whichever type of
small group is starting at that time in their site.
Approach to missing laboratory data
Although our initial analyses will use only observed data,
we will use logistic regression to model patients’ likeli-
hood of having outcome data and define strata within
which outcome values are missing at random. We will
then stratify patients according to these propensities and
randomly sample from the observed outcome distribu-
tion and impute these values for missing data within
each stratum. Additional sensitivity analyses will also be
conducted assuming no change in values for participants
for whom we are missing data and using multiple imput-
ation approaches for missing data.
Aim 2
To test for differences in resource use by active treat-
ment group status (SMA-only versus SMA + P2P), we
will use multivariable models similar to those for aim 1.
In addition, since counts of resource utilization are usu-
ally quite skewed, alternative modeling techniques, such
as Poisson regression, negative binomial regression, or a
generalized gamma regression will be used as appropri-
ate. Patients in the SMA-only and SMA + P2P groups
who agree to participate in the study will complete the
surveys of patient-centered outcomes at baseline, 6
months, and 12 months, allowing for comparisons
between outcomes among participants in these two
groups. In addition to producing descriptive statistics for
all of the scales described above, we will use mixed-
effects models (similar to those in aims 1) for continu-
ous outcomes and generalized estimating equations
(GEE) for ordinal outcomes with clustering.
Aim 3
Analysis of the qualitative data from the post-
implementation interpretive evaluation will follow a
published methodology for coding and rating CFIR
constructs [20]. Once the data has been coded to CFIR
constructs, an ordinal value (−2, −1, 0, 1, or 2) will be
assigned to each construct at each site. The values
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represent the perceived magnitude and “role” of each
construct in the implementation of the program. The
data will be used to construct a matrix for identifying
potential correlations between each construct and pro-
gram outcomes. The findings can be used to develop
recommendations for future efforts to disseminate the
program, depending on what these factors are, and how
they are manifested in the individual sites. We have used
this rating process successfully to identify those
constructs that appear to be most closely correlated with
intervention outcomes in seven different national evalu-
ations of VA programs [21]. The process provides a
systematic means of linking constructs to implementa-
tion success and allows for the analysis of data across
multiple studies using Qualitative Comparative Analysis.
Aim 4
To estimate the cost of the SMA and P2P clinical programs,
staff are asked to record the time spent on program-related
activities during a week-long data collection period. This data
is used to estimate the ongoing time involved in running the
programs, including time spent on recruiting participants,
face-to-face time, and charting. Staff are also asked to esti-
mate the amount of time spent on planning activities
required to initially implement SMAs and P2P.
Data monitoring
As both programs under evaluation, the SMAs and the
P2P program, are being offered as part of clinical care at
the participating facilities, this study is not required to
report to a Data Monitoring Committee.
Harms
There are no treatments, procedures, or interventions as
part of this study. Both patient and employee partici-
pants are given a Study Information Sheet with contact
information for study staff. Participants are encouraged
to contact study staff with any complaints/concerns
about the study. We will also ask about any concerns
expressed at the biweekly team conference calls. Finally,
during the follow-up interviews both patients and staff
will be asked to describe any problems that they experi-
enced, so that these can be addressed for future patients.
Any complaints or concerns expressed to the study staff
by participants, providers, or anyone else affected by this
study are immediately reported to the VA CIRB, as will
any unexpected events or problems.
Auditing
Annual audits of regulatory binders and HIPAA authori-
zations are conducted by the local research compliance
officers. Internal audits of the study database are
conducted by the coordinating center at quarterly
intervals for each site.
Discussion
Rationale for undergoing the trial
For diabetic patients, effective diabetes SM is a key
determinant of diabetes outcomes. In the face of evi-
dence from efficacy trials that examined diabetes SMAs
and reciprocal peer support models separately, there is
the need now for large-scale trials and implementation
studies that measure real-world impacts of these pro-
grams on patient-centered and staff-centered outcomes,
costs, and utilization. This study will provide important
information on the comparative effectiveness of these
programs and barriers that affect the implementation of
these programs within existing clinical processes. If aug-
menting SMAs with a P2P program is found to be
effective, this model could be used to improve health
outcomes among patients with other chronic conditions
requiring significant SM such as depression, chronic
pain, and congestive heart failure.
Dissemination policy
There are three major components to our dissemination
plan: (1) incorporation of the program as part of VA’s
Patient-aligned Care Teams (PACT) initiative, (2) limit-
ing the resource requirements for the program, and (3)
designing a toolkit for implementation (including refine-
ments of the training materials in this proposal’s appen-
dices). Regarding the first component, as participants in
the VA Ann Arbor PACT Demo Laboratory, our investi-
gators developed a computer-based “Navigator” system
for matching patients to various clinical programs based
on their preferences and needs. Patients’ clinical charac-
teristics are obtained from a local registry, and their
preferences for types of programs are obtained by the
Navigator nurse, all of which are used by a computer-
based algorithm to suggest specific programs. The
system is designed to emphasize a key aspect of a sus-
tainable care management program—efficiently targeting
patients for clinically appropriate programs. Incorporat-
ing SMAs and P2P as part of the system will facilitate its
inclusion as an important component of PACT and will
promote the PACT goal of providing patients with
patient-centered care, when they need it and how and
where they want it delivered. Disseminating the
Navigator at the same time that we promote the dissem-
ination of SMAs and P2P should provide facilities with a
way to integrate these programs within the constellation
of local programs available for meeting patients’ needs
as part of PACT.
In addition, we have designed the P2P program to be
an adjunct to SMAs, group diabetes education sessions,
or other short-term diabetes or chronic disease SM
training programs that are already a part of the patient
care process in many VA medical centers. While some
investment of effort is required on the part of
Heisler et al. Trials  (2017) 18:239 Page 8 of 10
participating facilities (i.e., training the P2P group facilita-
tors in MI communications techniques, conducting the
groups), we believe that this investment is relatively small
and should not impede the program’s dissemination in the
event that the program is found to be effective.
Finally, we will use our qualitative findings to develop
specific recommendations for implementation and to re-
fine materials that can be incorporated into an imple-
mentation toolkit.
Trial status
Patient recruitment started in May 2016 and will con-
tinue until April 2018. As of 15 May, 2017, the study has
enrolled 304 participants (target = 800) and 238 of those
have completed the baseline survey.
Additional file
Additional file 1: Figure S1. SPIRIT Checklist. (PDF 135 kb)
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